Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001947 | 1.00 | C3AR1 (0.34) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL21915057 | 1.00 | C3AR1 (0.34) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL23106105 | 0.90 | C3AR1 (0.34) | C3AR1FURINRENSIRT5SIRT6 | |
| SCHEMBL23393940 | 0.90 | SIRT5 (0.39) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL18818915 | 0.90 | REN (0.34) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL23106038 | 0.89 | NPY4R (0.39) | FURIN | |
| SCHEMBL20795891 | 0.89 | FURIN (0.36) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL23736705 | 0.89 | FURIN (0.36) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL21103418 | 0.89 | SIRT5 (0.36) | C3AR1FURINLMNAPOLBKMT2A | |
| SCHEMBL1711524 | 0.89 | C3AR1 (0.44) | C3AR1FURINPOLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | C3AR1 796/4885FURIN 3503/4885LMNA 4568/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | C3AR1 211/4885FURIN 4304/4885LMNA 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.